• News
    • News
    • Upcoming Events
    • Subscribe
  • Our Company
    • Our Story
    • Our Vision
    • CEO Statement
    • Board of Directors
    • Alzinova Team
    • Advisers & Collaborators
  • Patients & Families
    • Alzheimer's Patients
    • Impact on Society
    • The Unmet Medical Need
  • R & D
    • Alzheimer's Disease
    • Our Programs
    • Specific Targeting of Toxic Aβ Oligomers
    • The AβCC Peptide™ Technology
  • Investors
    • Overview
    • Rights Issue / Företrädesemission 2022
    • Press Releases
      • English
      • Swedish
      • Subscribe
    • Presentations
    • Company Presesentation
    • The Share
      • Share Information
      • Largest Shareholders
      • Share Capital Development
      • Rights Issues / Företrädesemissioner
      • Previous Share Issuances
      • Analyst Coverage
    • Financial Reports
      • English
      • Swedish
    • Financial Calendar
    • Corporate governance
      • General Meetings
      • Nomination Committee / Valberedning
      • Auditor
      • Articles of Association
      • Board of Directors
      • Management
    • Certified Adviser
    • IR Contact
  • Career
  • Contact
logo
  • News
    • News
    • Upcoming Events
    • Subscribe
  • Our Company
    • Our Story
    • Our Vision
    • CEO Statement
    • Board of Directors
    • Alzinova Team
    • Advisers & Collaborators
  • Patients & Families
    • Alzheimer's Patients
    • Impact on Society
    • The Unmet Medical Need
  • R & D
    • Alzheimer's Disease
    • Our Programs
    • Specific Targeting of Toxic Aβ Oligomers
    • The AβCC Peptide™ Technology
  • Investors
    • Overview
    • Rights Issue / Företrädesemission 2022
    • Press Releases
      • English
      • Swedish
      • Subscribe
    • Presentations
    • Company Presesentation
    • The Share
      • Share Information
      • Largest Shareholders
      • Share Capital Development
      • Rights Issues / Företrädesemissioner
      • Previous Share Issuances
      • Analyst Coverage
    • Financial Reports
      • English
      • Swedish
    • Financial Calendar
    • Corporate governance
      • General Meetings
      • Nomination Committee / Valberedning
      • Auditor
      • Articles of Association
      • Board of Directors
      • Management
    • Certified Adviser
    • IR Contact
  • Career
  • Contact
Home / Investors / Financial Reports
  • Overview
  • Rights Issue / Företrädesemission 2022
  • Press Releases
    • English
    • Swedish
    • Subscribe
  • Presentations
  • Company Presentation
  • The Share
    • Share Information
    • Largest Shareholders
    • Share Capital Development
    • Rights Issues / Företrädesemissioner
    • Analyst Coverage
  • Financial Reports
    • English
    • Swedish
  • Financial Calendar
  • Corporate Governance
    • General Meetings
    • Nomination Committee / Valberedning
    • Previous Nomination Committees
    • Auditor
    • Articles of Association
    • Board of Directors
    • Management
  • Certified Adviser
  • IR Contact

Financial Reports

The financial year for Alzinova follows the calendar year.  Financial reports are prepared in accordance with the Swedish Annual Accounts Act and the general recommendations of the Swedish Accounting Standards Board, and further presented according to the requirements from Nasdaq First North Grow Market.

en
  • News
  • Our Company
  • Patients & Families
  • R & D
  • Investors
  • Contact

Alzinova AB. Pepparedsleden 1, SE-431 83, Mölndal, Sweden
+46 (0) 708 467 975   info@alzinova.com

Follow us on

follow us on linkedin